TScan Therapeutics (TCRX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TCRX TScan Therapeutics

Watchlist

3.330
-1.310-28.23%

Close Dec 10 16:00 ET

3.390
+0.060+1.80%

Pre 08:55 ET

177.72MMarket Cap-3.51P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $11
Moomoo News31minutes ago · Ratings
TScan Therapeutics Price Target Maintained With a $11.00/Share by Needham
Dow Jones38minutes ago · Ratings
LifeSci Capital Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $12
Moomoo News17:31 ET · Ratings
TScan Therapeutics Announces Promising Phase 1 Trial Results
TipRanksDec 10 08:31 ET
Promising Outcomes and Favorable Safety Profile Drive Buy Rating for TScan Therapeutics' TSC100/101 Program
TipRanksDec 10 07:06 ET · Ratings
TScan Therapeutics To Present Updated Results From Ongoing ALLOHA Phase 1 Trial Of TSC-100 And TSC-101 At ASH Meeting
BenzingaDec 9 17:52 ET

Comments

Trytosaveabit

Yesterday 06:55

Watching

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics To Present Updated Results From Ongoing ALLOHA Phase 1 Trial Of TSC-100 And TSC-101 At ASH Meeting
Benzinga· 1 min ago
TSC-100 and TSC-101 are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning.
The company said it is high...

MARKET-TEST-DUMMY

Dec 7 05:06

👁

$TScan Therapeutics (TCRX.US)$

Jaguar8

Nov 5 08:16

NEWS

$TScan Therapeutics (TCRX.US)$
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Jaguar8

Oct 4 10:40

NEWS

$TScan Therapeutics (TCRX.US)$
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentationat the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houst...

Trytosaveabit

May 29 06:08

News

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Says FDA Granted Regenerative Medicine Advanced Therapy Designation To TSC-100 And TSC-101
Benzinga· 2 mins ago

Heat List

Overall

No Data